Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QuickStrip CBD
- Development stage
- Unknown
- Lead developer
- Rapid Dose Therapeutics
- Modality
- Small Molecules
- Administration
- Sublingual, Buccal
01
Overview
QuickStrip CBD is a cannabidiol (CBD) delivery product developed by Rapid Dose Therapeutics using its proprietary QuickStrip™ oral thin film technology. The product consists of a thin, fast-dissolving film infused with micronized CBD isolate, designed for sublingual or buccal administration. This delivery method allows the active ingredient to be absorbed directly into the bloodstream through the oral mucosa, bypassing the gastrointestinal tract and first-pass metabolism in the liver, which is intended to improve bioavailability and provide a more rapid onset of action compared to traditional oral formats. As of 2024, the product is being evaluated in a bioavailability study in collaboration with the University of Regina and the University of Saskatchewan, with funding from the National Football League (NFL) to explore its potential in pain management and neuroprotection for contact sports.
- Brand names
- QuickStrip CBDQuickStrip
- Other names
- QuickStrip™ CBD
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)GABRR (GABA-A receptor subunit rho)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPM8 (Transient receptor potential cation channel subfamily M member 8)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on QuickStrip CBD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QuickStrip CBD.